The Diagnostic Value of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU

NCT ID: NCT06353659

Last Updated: 2024-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-15

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to quantitatively assess the renal microcirculation changes by contrast-enhanced ultrasound (CEUS) and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore the diagnostic value of CEUS in critically ill acute kidney injury.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main questions it aims to answer are:

1. To explore the quantitative parameters of contrast-enhanced ultrasound which can reflect the changes of renal microcirculation。
2. To explore the relationship between renal microcirculation and systemic hemodynamics。
3. To explore the value of quantitative evaluation of renal microcirculation changes by contrast-enhanced ultrasound in the diagnosis of acute kidney injury

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intensive Care Unit Acute Kidney Injury Ultrasound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with acute kidney injury (AKI)

Patient diagnosed with AKI according to kidney disease improving global outcomes (KDIGO) 2012 criteria

Contrast-enhanced Ultrasound

Intervention Type DIAGNOSTIC_TEST

Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU

Patients without AKI

Patient diagnosed without AKI according to kidney disease improving global outcomes (KDIGO) 2012 criteria

Contrast-enhanced Ultrasound

Intervention Type DIAGNOSTIC_TEST

Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Contrast-enhanced Ultrasound

Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\>18 years old
* First admission to ICU \< 24h after admission and expected ICU stay ≥48 hours
* Acute kidney injury risk factors (KDIGO 2012)
* Contrast-enhanced ultrasound

Exclusion Criteria

* Known severe chronic kidney disease (CKD≥ stage 4) or undergoing hemodialysis treatment
* Kidney transplantation or renal malignancy
* Terminal stage of malignant tumor
* Pregnancy
* Renal artery stenosis or renal vein thrombosis
* The quality of CEUS images is poor, and quantitative analysis cannot be performed
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University Third Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cui Ligang

Chief Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ligang Cui, Dr

Role: PRINCIPAL_INVESTIGATOR

Department of Ultrasound, Peking University Third Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuewei Zhang, Dr

Role: CONTACT

18800109082

Ligang Cui, Dr

Role: CONTACT

13910627163

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M2024077

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.